| Literature DB >> 24396425 |
Tomoko Takamaru1, Goro Kutomi1, Fukino Satomi1, Hiroaki Shima1, Keisuke Ohno1, Hidekazu Kameshima1, Yasuyo Suzuki1, Tousei Ohmura1, Hiroyuki Takamaru2, Masanori Nojima3, Mitsuru Mori3, Koichi Hirata1.
Abstract
For sentinel lymph node biopsy (SLNB), a combination of dye-guided and γ-probe-guided methods is the most commonly used technique. However, the number of institutes in which the γ-probe-guided method is able to be performed is limited, since special equipment is required for the method. In this study, SLNB with the dye-guided method alone was evaluated, and the clinicopathological characteristics were analyzed to identify any factors that were predictive of whether the follow-up axillary lymph node dissection (ALND) was able to be omitted. A total of 374 patients who underwent SLNB between 1999 and 2009 were studied. The SLN identification rate was analyzed, in addition to the false-positive and false-negative rates and the correlation between the clinicopathological characteristics and axillary lymph node metastases. The SLN was identified in 96.8% of cases, and, out of the patients who had SLN metastasis, 63.0% did not exhibit metastasis elsewhere. The sensitivity was 96.4% and the specificity was 100%. The false-negative rate was 3.6%. Univariate analyses revealed significant differences in the lymph vessel invasion (ly) status, nuclear grade (NG), maximum tumor size and the percentage of the area occupied by the tumor cells in the SLN (SLN occupation ratio) between the patients with and without non-SLN metastasis, indicating that these factors may be predictive of axillary lymph node metastasis. Multivariate analysis revealed that ly status was an independent risk factor for non-SLN metastasis. In conclusion, SLN with the dye-guided method alone provided a high detection rate. The study identified a predictive factor for axillary lymph node metastasis that may improve the patients' quality of life.Entities:
Keywords: axillary lymph node dissection; breast cancer; dye-guided method; prediction of lymph node metastasis; sentinel lymph node biopsy
Year: 2013 PMID: 24396425 PMCID: PMC3881064 DOI: 10.3892/etm.2013.1445
Source DB: PubMed Journal: Exp Ther Med ISSN: 1792-0981 Impact factor: 2.447
Characteristics of 374 patients who underwent SLNB.
| Clinical features | No. of patients (%) |
|---|---|
| Mean age, years (range) | 56.7 (23–87) |
| Location of tumor | |
| Medial | 103 (27.5) |
| Lateral | 264 (70.6) |
| Central | 7 (1.9) |
| Clinical tumor stage | |
| T0 | 14 (3.7) |
| T1 | 175 (46.8) |
| T2 | 161 (43.0) |
| T3 | 19 (5.1) |
| T4 | 5 (1.3) |
| Clinical nodal stage | |
| N0 | 332 (88.8) |
| N1 | 41 (11.0) |
| N2 | 1 (0.3) |
| N3 | 0 (0.0) |
| No. of SLN | |
| 1 | 149 (39.8) |
| 2 | 130 (34.8) |
| 3 | 56 (15.0) |
| 4 | 18 (4.8) |
| ≥5 | 9 (2.4) |
| Not detected | 12 (3.2) |
SLNB, sentinel lymph node biopsy.
Figure 1Patient status. SLNB, sentinel lymph node biopsy; SLN, sentinel lymph node; ALND, axillary lymph node dissection.
Diagnosis of sentinel lymph node metastases.
| A. Postoperative diagnosis | |||
|---|---|---|---|
|
| |||
| Postoperative diagnosis | SLN or non-SLN-positive | SLN and non-SLN-negative | Total |
| SLN-positive | 54 | 0 | 54 |
| SLN-negative | 2 | 47 | 49 |
| Total | 56 | 47 | 103 |
|
| |||
| B. Intraoperative diagnosis | |||
|
| |||
| Intraoperative diagnosis | SLN-positive | SLN-negative | Total |
|
| |||
| SLN-positive | 54 | 0 | 54 |
| SLN-negative | 8 | 300 | 308 |
| Total | 62 | 300 | 362 |
Postoperative diagnosis: The sensitivity for sentinel lymph node (SLN) metastasis was 96.4%, the specificity was 100% and the false-negative rate was 3.6%. Intraoperative diagnosis: A diagnostic accuracy of 97.8%, a sensitivity of 87.1% and specificity of 100% were achieved with hematoxylin and eosin (H&E) staining in the frozen sections; the false-negative rate was 12.9%.
Clinicopathological factors correlated with non-SLN metastasis.
| Clinical feature | SLN only | SLN and non-SLN | P-value |
|---|---|---|---|
| Mean age (years) | 59.76 | 59.85 | 0.9820 |
| Tumor size (cm) | 2.34 | 2.92 | 0.0317 |
| ly | 0.0002 | ||
| ly0 | 12 | 0 | |
| ly1–3 | 20 | 20 | |
| v | 0.2346 | ||
| v0 | 29 | 15 | |
| v1 | 3 | 5 | |
| NG | 0.0433 | ||
| 1 | 20 | 6 | |
| 2–3 | 11 | 12 | |
| Unknown | 3 | 2 | |
| ER status | 0.7208 | ||
| Negative | 7 | 3 | |
| Positive | 24 | 17 | |
| Unknown | 3 | 0 | |
| PgR status | |||
| Negative | 10 | 2 | 0.0949 |
| Positive | 21 | 18 | |
| Unknown | 3 | 0 | |
| HER2 status | 0.6958 | ||
| Negative | 27 | 16 | |
| Positive | 4 | 4 | |
| Unknown | 3 | 0 | |
| SLN occupation ratio (%) | 21.47 | 46.75 | 0.0017 |
P-values were calculated using either the t-test or the χ2 test.
P<0.05,
P<0.01.
SLN, sentinal lymph node; ly, lymph vessel invasion; v, vessel invasion; NG, nuclear grade; ER, estrogen receptor; PgR, progesterone receptor; HER2, human epidermal growth factor type 2; SLN occupation ratio, percentage of SLN area occupied by tumor cells.
Multivariate analysis.
| Risk factor for SLN metastasis | P-value | Relative risk | 95% CI |
|---|---|---|---|
| Age | 0.0938 | 1.00 | 0.93–1.07 |
| Maximum tumor size | 0.1477 | 2.09 | 0.81–8.24 |
| ly | |||
| ly0 | 0.0138 | 1.00 | 1.95–5.14×1019 |
| ly1–3 | 7.08×108 | ||
| v | |||
| v0 | 0.4950 | 1.00 | 0.27–20.47 |
| v1 | 2.03 | ||
| NG | |||
| 1 | 0.1258 | 1.00 | 0.68–29.32 |
| 2–3 | 4.05 | ||
| ER status | |||
| Negative | 0.8965 | 1.00 | 0.105–12.33 |
| Positive | 1.16 | ||
| PgR status | |||
| Negative | 0.0823 | 1.00 | 0.791–145.56 |
| Positive | 7.30 | ||
| HER2 status | |||
| Negative | 0.2760 | 1.00 | 0.43–25.07 |
| Positive | 3.00 | ||
P<0.05.
SLN, sentinel lymph node; CI, confidence interval; ly, lymph vessel invasion; v, vessel invasion; NG, nuclear grade; ER, estrogen receptor; PgR, progesteron receptor; HER2, human epidermal growth factor type 2.